Detalles de la búsqueda
1.
miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness.
Int J Cancer
; 133(7): 1614-23, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23526361
2.
PIK3R1 underexpression is an independent prognostic marker in breast cancer.
BMC Cancer
; 13: 545, 2013 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-24229379
3.
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
BMC Cancer
; 13: 351, 2013 Jul 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-23875536
4.
Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study.
Int J Cancer
; 131(2): 426-37, 2012 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21898387
5.
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.
Breast Cancer Res Treat
; 132(3): 895-915, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048814
6.
Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy.
Mol Cancer
; 10: 23, 2011 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-21352579
7.
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.
BMC Cancer
; 11: 215, 2011 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21631949
8.
Immunomarker studies of fine-needle cytopuncture cell blocks for tumor response prediction after preoperative chemotherapy and prognosis in operable nonmetastatic primary breast carcinoma.
Breast J
; 17(2): 121-8, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21306468
9.
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
BMC Cancer
; 10: 247, 2010 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20515469
10.
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Clin Cancer Res
; 15(1): 315-23, 2009 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19118060
11.
Response to "comments on the use of a single or multiple probe-set approach for microarray-based analyses of routine molecular markers in breast cancer".
Breast Cancer Res Treat
; 137(2): 650-1, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23413459
12.
COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
Anticancer Res
; 38(3): 1485-1490, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29491076
13.
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.
Breast Cancer Res
; 9(3): R33, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17535433
14.
Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: a candidate biomarker to predict EGFR inhibitor effectiveness.
Int J Cancer
; 131(4): 1009-10, 2012 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21918978
15.
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Eur J Cancer
; 43(11): 1679-86, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17601725
16.
Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer.
Breast Cancer Res Treat
; 134(1): 443-8, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22527097
17.
Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.
Anticancer Res
; 27(4C): 2689-96, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17695434
18.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
J Natl Cancer Inst
; 94(2): 116-28, 2002 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-11792750
19.
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
Thromb Haemost
; 90(3): 538-48, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12958624
20.
Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma.
Cancer Lett
; 215(1): 101-12, 2004 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-15374639